PUMA BIOTECHNOLOGY INC

Discover how Puma Biotechnology is accelerating cancer drug development by in‑licensing proven candidates and offering promising investment potential in the biotech sector.

Explore Puma Biotechnology’s strategy to repurpose early‑stage cancer therapies, its recent Nasdaq rebound, and key investment metrics for 2026.

Puma Biotechnology Inc.’s recent partnership with Er-Kim for the distribution of NERLYNX represents a high-risk, high-reward strategy that could potentially propel the company to leadership in the cancer treatment landscape.

Puma Biotechnology is a development-stage biopharmaceutical company working to bring innovative cancer treatments to market through its strategic approach to drug development.